A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Inhibition of the prosurvival members of the Bcl-2 family of proteins represents an attractive strategy for the treatment of cancer. We have previously reported the activity of ABT-737, a potent inhibitor of Bcl-2, Bcl-X(L), and Bcl-w, which exhibits monotherapy efficacy in xenograft models of small-cell lung cancer and lymphoma and potentiates the activity of numerous cytotoxic agents. Here we describe the biological activity of A-385358, a small molecule with relative selectivity for binding to Bcl-X(L) versus Bcl-2 (K(i)'s of 0.80 and 67 nmol/L for Bcl-X(L) and Bcl-2, respectively). This compound efficiently enters cells and co-localizes with the mitochondrial membrane. Although A-385358 shows relatively modest single-agent cytotoxic activity against most tumor cell lines, it has an EC(50) of <500 nmol/L in cells dependent on Bcl-X(L) for survival. In addition, A-385358 enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents (paclitaxel, etoposide, cisplatin, and doxorubicin) in several tumor cell lines. In A549 non-small-cell lung cancer cells, A-385358 potentiates the activity of paclitaxel by as much as 25-fold. Importantly, A-385358 also potentiated the activity of paclitaxel in vivo. Significant inhibition of tumor growth was observed when A-385358 was added to maximally tolerated or half maximally tolerated doses of paclitaxel in the A549 xenograft model. In tumors, the combination therapy also resulted in a significant increase in mitotic arrest followed by apoptosis relative to paclitaxel monotherapy.

[1]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[2]  P. N. Rao,et al.  The mitosis-specific monoclonal antibody MPM-2 recognizes phosphoproteins associated with the nuclear envelope in Chlamydomonas reinhardtii cells. , 1990, European journal of cell biology.

[3]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[4]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[5]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[6]  John Calvin Reed,et al.  Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.

[7]  J. Ben-Ezra,et al.  Small cell carcinomas of the lung express the Bcl-2 protein. , 1994, The American journal of pathology.

[8]  J. Lee,et al.  Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  John Calvin Reed.  Bcl-2 family proteins: regulators of chemoresistance in cancer. , 1995, Toxicology letters.

[10]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[11]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[12]  G. Núñez,et al.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. , 1997, Blood.

[13]  O. Olopade,et al.  Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. , 1997, The cancer journal from Scientific American.

[14]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[15]  John Calvin Reed,et al.  Estrogen withdrawal‐induced human breast cancer tumour regression in nude mice is prevented by Bcl‐2 , 1998, FEBS letters.

[16]  S. Leach,et al.  Mitotic Phosphorylation of Bcl-2 during Normal Cell Cycle Progression and Taxol-induced Growth Arrest* , 1998, The Journal of Biological Chemistry.

[17]  D. Arber,et al.  Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[18]  C. Rudin,et al.  Bcl-xL is phosphorylated in malignant cells following microtubule disruption. , 1998, Cancer research.

[19]  "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. , 1998, Cancer research.

[20]  S. Korsmeyer,et al.  Solution Structure of the Proapoptotic Molecule BID A Structural Basis for Apoptotic Agonists and Antagonists , 1999, Cell.

[21]  Junying Yuan,et al.  Solution Structure of BID, an Intracellular Amplifier of Apoptotic Signaling , 1999, Cell.

[22]  L. Milas,et al.  Combination of taxanes with radiation: preclinical studies. , 1999, Seminars in radiation oncology.

[23]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[24]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[26]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[27]  D. Fennell,et al.  In vivo suppression of Bcl‐XL expression facilitates chemotherapy‐induced leukaemia cell death in a SCID/NOD‐Hu model , 2001, British journal of haematology.

[28]  S. Lowe,et al.  Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. , 2001, Blood cells, molecules & diseases.

[29]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[30]  A. Petros,et al.  Solution structure of the antiapoptotic protein bcl-2 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[32]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[33]  John Calvin Reed,et al.  Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. , 2001, Neoplasia.

[34]  S. Ng,et al.  Development of a high-throughput fluorescence polarization assay for Bcl-x(L). , 2002, Analytical biochemistry.

[35]  A. Gillum,et al.  Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. , 2002, Antisense & nucleic acid drug development.

[36]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[37]  S. Ng,et al.  Development of a high-throughput fluorescence polarization assay for Bcl-x(L). , 2002, Analytical biochemistry.

[38]  M. Lackmann,et al.  The structure of Bcl‐w reveals a role for the C‐terminal residues in modulating biological activity , 2003, The EMBO journal.

[39]  K. Gehring,et al.  Solution Structure of Human BCL-w , 2003, Journal of Biological Chemistry.

[40]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[41]  A. Petros,et al.  Structural biology of the Bcl-2 family of proteins. , 2004, Biochimica et biophysica acta.

[42]  Maurizio Pellecchia,et al.  Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. , 2004, Chemistry & biology.

[43]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[44]  À. Sierra,et al.  Overexpression of Bcl-xL in Human Breast Cancer Cells Enhances Organ-Selective Lymph Node Metastasis , 2004, Breast Cancer Research and Treatment.

[45]  G. Daley,et al.  A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth , 2004, Oncogene.

[46]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[47]  E. White,et al.  Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.

[48]  S. Kulp,et al.  Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. , 2005, Cancer research.

[49]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[50]  A. Petros,et al.  Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. , 2006, Journal of medicinal chemistry.